Search
ProQR Therapeutics NV
PRQRAdd to Watchlist
1.555USD
-0.065-4.01%
Market hours 10/13, 11:47（ET）
206.80MMarket Cap
LossP/E TTM
ProQR Therapeutics NV (PRQR) Stock Price Target & Forecast
Analyst Rating
Based on 9 analysts giving stock ratings to ProQR Therapeutics NV in the past month.
Buy
3 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
8.500USD+421.47%
PRQR Analyst Recommendation Trends
In the current month, PRQR has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PRQR average Analyst price target in the last month is 8.500.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
3
3
3
3
3
3
3
3
6
6
6
6
6
6
6
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
9
9
9
9
9
9
9
PRQR Analyst Rating for Peer Comparison
Updated: Oct 12, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
18
0
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
14
1
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
IQVIA Holdings Inc
IQV
8
11
3
0
0
22
Biontech SE
BNTX
4
13
5
0
0
22
Financial Forecasting
Based on analysts' estimates, PRQR EPS is projected to reach -0.110 in FY2026Q3, following reported EPS of -0.091 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.11
-0.13
-0.13
-0.11
-0.12
Actual
-0.10
-0.15
-0.09
--
--
Surprise
+12.48%
-9.50%
+29.03%
--
--
FAQs
What is ProQR Therapeutics NV's expected revenue for the next quarter?
ProQR Therapeutics NV's expected revenue is 4.95M.
What is ProQR Therapeutics NV's price target?
Analysts forecast that ProQR Therapeutics NV's price target is USD 8.50, with the highest forecast at USD 15.00 and the lowest forecast at USD 3.00.
How have ProQR Therapeutics NVPRQR's recent earnings per share performed?
The market expectation was USD -0.09, while ProQR Therapeutics NVPRQR's earnings per share (EPS) for the previous quarter was USD -0.15. EPS for the next quarter is expected at USD -0.11.
What is the analyst rating for ProQR Therapeutics NV?
Based on the ratings of ProQR Therapeutics NV's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.